Trial Profile
A Phase 1/2 Study of Alefacept, a CD2 Receptor Antagonist in Patients With Relapsed/Refractory Aplastic Anemia
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Alefacept (Primary)
- Indications Aplastic anaemia
- Focus Adverse reactions; Therapeutic Use
- 24 Jan 2018 Status changed from suspended to discontinued.
- 30 Jun 2014 New trial record
- 10 Dec 2013 Results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.